KYBELLA™ is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat under the chin, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. In clinical trials, many patients experienced visible results in two to four treatments, though up to six treatments may be administered.
“We are excited to be able to offer a new option for patients with submental fullness,” said Dr. Lawrence. “Submental fullness is a common yet undertreated condition that can detract from an otherwise balanced and harmonious facial appearance leading to an older and heavier look.”
Submental fullness can affect adults – both women and men – of all ages, weight and gender. Influenced by multiple factors including aging and genetics, submental fullness is often resistant to diet and exercise. According to a survey by the American Society for Dermatologic Surgery, nearly as many consumers are bothered by submental fullness (68 percent) as by lines and wrinkles around the eyes (71 percent).
KYBELLA™ should only be administered by a trained health care professional and only physicians who have participated in a training program will be able to purchase KYBELLA™ and treat patients.
According to studies, 79 percent of KYBELLA™-treated patients reported satisfaction with their appearance in association with their face and chin. Patients also reported improvement in the visual and emotional impact of submental fat when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment in relation to the amount of their submental fat.
The treatment is not covered by medical insurance.